DENTSPLY SIRONA (XRAY) shares are in focus after the company and Siemens Healthineers received FDA clearance for MAGNETOM Free.Max Dental Edition, the first dental dedicated MRI system designed for non ionizing imaging across multiple dental specialties.

The FDA clearance comes as DENTSPLY SIRONA’s 1 day share price return of 4.18% contrasts with a weaker 30 day share price return of a 5.64% decline and a 1 year total shareholder return of an 18.57% decline. This suggests recent momentum is improving against a longer period of share price and dividend pressure.

If this kind of dental imaging progress has your attention, it could be a good moment to broaden your watchlist with other healthcare focused AI names via our 36 healthcare AI stocks

After years of weak total returns and a recent bump on the MRI news, XRAY now trades well below one estimate of intrinsic value and at a discount to analyst targets, so is there real upside left, or is future growth already priced in?

Most Popular Narrative: 73.1% Undervalued

According to user yiannisz, the narrative pegs DENTSPLY SIRONA's fair value at $45.50 versus a last close of $12.22, indicating a large gap between price and perceived worth.

Dentsply Sirona operates in a corner of healthcare that rarely attracts hype but consistently demands precision. As one of the world’s largest dental equipment and consumables providers, the company sits upstream from patient demand, selling to dental practices rather than consumers. That position shapes everything about its business, from revenue stability to growth expectations.

Curious what kind of revenue path and margin profile need to line up with that $45.50 figure? The narrative places emphasis on durable demand and a potentially richer future earnings mix. Want to see how those moving parts compare with today's $12.22 share price and the current revenue assumptions?

Result: Fair Value of $45.50 (UNDERVALUED)

However, that upside case still sits against some clear pressure points, including a recent 1 year total shareholder return decline of 18.57%, and a US$598 million net loss that could weigh on sentiment.

Next Steps

Given the mix of pressure points and potential rewards in this story, it makes sense to check the numbers yourself and decide where you stand. Start with the balance of 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If XRAY has sharpened your focus on risk, reward, and timing, do not stop here. Broaden your toolkit with screeners that surface very different types of opportunities.

• Target cash rich businesses that can weather tougher periods by scanning for companies in the solid balance sheet and fundamentals stocks screener (42 results).
• Spot potential mispricings quickly by checking companies highlighted in the 49 high quality undervalued stocks.
• Uncover names that still sit off most radars by reviewing the screener containing 27 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.